Q1 Earnings Estimate for STOK Issued By HC Wainwright

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Stoke Therapeutics in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.53) for the quarter. HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.54) EPS.

A number of other brokerages have also issued reports on STOK. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $8.33 on Thursday. The firm’s 50-day moving average is $9.49 and its two-hundred day moving average is $11.49. The stock has a market capitalization of $441.22 million, a P/E ratio of -3.97 and a beta of 0.99. Stoke Therapeutics has a 12-month low of $5.80 and a 12-month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of STOK. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics during the fourth quarter worth approximately $63,000. Teacher Retirement System of Texas purchased a new stake in Stoke Therapeutics during the 4th quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in Stoke Therapeutics during the 4th quarter worth $124,000. Tower Research Capital LLC TRC increased its holdings in Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after purchasing an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. purchased a new position in Stoke Therapeutics in the fourth quarter valued at about $133,000.

Insiders Place Their Bets

In other news, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 over the last quarter. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.